Medical Marijuana Uses: Cannabis Calms IBS
Posted by Marijuana Doctors on 09/15/2011 in Medical Marijuana Conditions
There’s some good news for patients suffering from Irritable Bowel Syndrome. Cannabis was recently proven to decrease colonic motility in patients with irritable bowel syndrome (IBS), according to a study called “Pharmacogenetic Trial of a Cannabinoid Agonist Shows Reduced Fasting Colonic Motility in Patients with Non-Constipated Irritable Bowel Syndrome.”
For those unfamiliar with IBS, it is a disorder that leads to abdominal pain and cramping, changes in bowel movements, and other symptoms. About 1 in 6 people in the U.S. have symptoms of IBS. It is the most common intestinal problem that causes patients to see a gastroenterologist. A recent survey from the European Journal of Gastroenterology and Hepatology shows that it’s very common for patients with IBS regularly use medical marijuana to alleviate their symptoms. Now this new study confirms cannabis’ benefits for IBS patients.
This new cannabis/IBS study, which is published in the journal Gastroenterology, found that the administration of synthetic THC (aka dronabinol) is beneficial for those suffering with IBS. Researchers at the Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER) in Rochester, Minnesota studied 75 individuals with IBS—35 with IBS with constipation, 35 with IBS with diarrhea, and with 5 IBS alternating). Each test subject was randomly assigned to groups that were given 1 dose of placebo or 2.5 mg or 5.0 mg dronabinol. All participants given the synthetic THC showed decreased colonic motility, which is the contraction of intestinal muscles and movement of its contents. The most significant results in IBS patients with diarrhea and in subjects with alternating diarrhea and constipation.
Researchers concluded that “In patients with IBS with diarrhea or alternating, dronabinol reduces fasting colonic motility.” Dronabinol is presently a schedule III controlled substance that is currently is approved by the US Food and Drug Administration for the treatment of severe nausea and cachexia (wasting syndrome). But we may soon see the drub being approved for IBS thanks to the results of this new study.